Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 26, Issue 6, Pages 705-717Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2013.01.003
Keywords
Neuroendocrine tumour; Gastroenteric tract; WHO; TNM; ENETS; Ki67
Categories
Funding
- Italian Cancer Genome Project [FIRB RBAP10AHJB]
- Italian Association for Cancer Research (AIRC) [12182]
Ask authors/readers for more resources
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) constitute a heterogeneous group of neoplasms. In the last few decades, due to a substantial rise in incidence and prevalence, GEP-NETs have been included among the most common tumours of the gastrointestinal tract. Diagnosis could be challenging and a significant number of patients present with metastatic or unresectable disease. The development of appropriate tools for standardised prognostic stratification and the introduction of effective target therapies have opened new horizons for planning tailored surgical or medical management and follow-up programs for these complex neoplasms. An overview on the GEP-NETs' diagnostic and prognostic criteria proposed by the recently published WHO classification and ENETS and UICC TNM staging systems is presented, focussing on their impact on the clinical and therapeutical approaches. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available